Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am a little concerned too that no one is accumulating this if this decides to go.
Sounds good. Keep pushing forward SBFM, Thanks for the update
It looks like we may be on the verge of testing the 4's this week. Could very well be the day to buy.
Coming back now
Waiting to see where the low is today before putting a buy in. Dropping pretty quick this am.
Don't encourage it.
I second that. At least since I hit the ignore button things are easier to take here but if we all just stop replying to the useless posts it will be a perfect board to contribute to.
It's amazing how enjoyable it is to read the board now once you push the ignore button.
Had to use the ignore today. Had enough of the childish behavior. I've lost money on stocks before but never hung around and tortured others on a stock board with useless unecessary posts. Thanks to the members who post useful info and restrain themselves from the caps!! lol
Angel seems to jump from basher to pumper depending on the day. Maybe he just likes to see his post count rising when he posts the same thing over and over .
I haven't been in this that long but it is good to see some decent volume . There seems to be interest. All we need is some positive news that will generate some steady volume and this will move up in a hurry. I'm still keeping positive.
If we can get the right volume this is ready for a run.
Usually when the bashers come out there is something brewing on the horizon.
Nice to see news, good volume and we almost made it through a trading day without the use of capitals. Maybe tomorrow!!!
Looking forward to the next update!!
Need more volume to get that bid up.
Another 5000 through at .19 :)
Glad to see some new faces here with a positive attitude and hopeful of good things to come for 2014. You have to skim through the posts or hit the ignore button for some who post here. GLTA
I'm not sure about the prayers but we do have an angel here. lol
Looking at these posts. He has to be.
Galena Biopharma Enrolls First Patient in GALE-301 (Folate Binding Protein (FBP)) Cancer Immunotherapy Phase 2 Clinical Trial in Ovarian Cancer
PORTLAND, Ore., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the first patient has been enrolled in the Phase 2 trial for GALE-301 (Folate Binding Protein (FBP) vaccine). GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy.
The optimized dose, along with the implementation of a booster regimen, will be used in the Phase 2 trial. The Phase 2 trial is an open-label trial with two arms consisting of HLA-A2 positive patients treated with the FBP peptide plus adjuvant versus active control. After an initial induction series of six vaccinations given once per month, patients will be boosted twice at 6-month intervals. The primary objective of the trial is to measure immune response, with secondary outcomes of recurrence.
"With GALE-301 progressing into its Phase 2 trial, we continue to demonstrate progress of our innovative cancer immunotherapy pipeline," said Mark J. Ahn, Ph.D., President and Chief Executive Officer. "Once recurrent, ovarian and endometrial cancers are two of the deadliest malignancies, therefore preventing metastatic disease is critical. We are encouraged by the promising early results of GALE-301 in addressing this critical unmet medical need."
Initial results from the Phase 1 trial determined the optimal dose and showed that GALE-301 was well tolerated and evoked a FBP specific immunological response. After a median follow-up of six months from completion of the vaccine series, there were 2 recurrences (13.3%; n=15) in the vaccine group vs. 4 recurrences (25%, n=16) in the control group, although the trial was not powered for any efficacy measurements.
About GALE-301 (Folate Binding Protein (FBP) vaccine)
GALE-301 (Folate Binding Protein (FBP)) cancer immunotherapy targets FBP, a well-validated therapeutic target whichis highly over-expressed in breast, ovarian and endometrial cancers. FBP is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy presenting FBP-expressing cancer cells. The FBP vaccine consists of the FBP peptide(s) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF). Galena's FBP vaccine is currently in a Phase 1/2 trial in two gynecological cancers: ovarian and endometrial adenocarcinomas.
About Ovarian/Endometrial Cancers
Ovarian cancer occurs in over 22,000 patients per year in the U.S. and is the most lethal gynecologic cancer. Despite the incidence of ovarian cancer being only approximately 20% of that of breast cancer, the number of patients that die from ovarian cancer is nearly 50% of that of breast cancer. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While most patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse, and once the disease recurs, the treatment options and successes drop dramatically.
Endometrial cancer is the most common gynecologic cancer and occurs in over 46,000 women, with over 8,000 deaths, in the U.S. annually. There are two basic types of endometrial cancer: endometrioid and papillary serous. The latter has a much more aggressive clinical course and the majority of these patients will die of this form of the disease.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about patient enrollment in our Phase 2 clinical trial, as well as statements about our expectations, plans and prospects of our GALE 301 product candidate. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.
CONTACT: Remy Bernarda
VP, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
Source: Globe Newswire (January 7, 2014 - 7:05 AM EST)
This one has the potential to run but keeps getting it's legs broke on the last trade of the day!! Maybe next week?
I think there is great upside potential. I took a position and will see what 2014 brings. Some decent news could be a great catalyst to move this upwards.
Merry Christmas Boo. Thanks for all your insight. Happy Holidays!
I'm feeling this is the right time to jump on board. We'll see what happens.
Appreciate the CAPS!!
I think most of these pumping posts are just the same person with different nicknames . I think the true investors will filter out the garbage and read through the crap and focus on the informative posts.
I'm curious how quick this will move with any news with some substance. Just bought in on this yesterday.
Got some filled today at .15
Looking forward to being in on this when it does go. I think the ignore button will come in handy here for some.
Is there no ban button.
I tried .13 and .14 and .15 but no takers yet. Will let it sit and see.
No fill again at .15 :(
No fill today at .15 Will keep plugging away.
Thanks G. Will be back at it on Monday.
Hey guys. I'm new to SBFM. Tried to buy some today at .15 and .155 but no takers today. Will try again on Monday and see if there are any cheap shares up for grabs. I'll read up on the posts for more info. Any info is appreciated.
December 4, 2013
Galena Biopharma to Present at the Oppenheimer 24th Annual Healthcare Conference
PORTLAND, Ore., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the Oppenheimer 24th Annual Healthcare Conference. The presentation will take place on Tuesday, December 10, 2013 at 10:55 a.m. ET at the Crowne Plaza Hotel in New York, NY.
The presentation will be webcast and available on the Investors section of the Company's website at www.galenabiopharma.com.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit: www.galenabiopharma.com.
CONTACT: Remy Bernarda
Vice President, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
Close window | Back to top
November 26, 2013
Galena Biopharma to Present at the 25th Annual Piper Jaffray Healthcare Conference
PORTLAND, Ore., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 25th Annual Piper Jaffray Healthcare Conference. The presentation will take place on Tuesday, December 3, 2013 at 8:10 a.m. ET at The New York Palace Hotel in New York, NY.
The presentation will be webcast and available on the Investors section of the Company's website at www.galenabiopharma.com.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit: www.galenabiopharma.com.
CONTACT: Remy Bernarda
Senior Director, Communications
(503) 405-8258
rbernarda@galenabiopharma.com
If it goes up another 80 - 100 percent tomorrow I will be in the green!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Can't argue with you, but I am trying to be somewhat positive when the stock looks so negative.